Poulami Chatterjee

"GCCs are using AI models trained on real-world evidence and longitudinal EHR data to identify new indications for existing drugs… These models not only accelerate development timelines but also reduce R&D risk.” — Karthik Padmanabhan, Managing Partner, Zinnov, in a recent article by Business Standard Across India’s Global Capability Centers (GCCs), teams are already using AI to identify new molecules with greater precision. They are working with start-ups to bring down quality checks from hours to minutes. Algorithms are simulating compounds, predicting efficacy before a single lab test, and making clinical trials smarter. As the article below points out, what once took 10–14 years to bring to market is now being compressed. Timelines are shorter. Risks are lower. Breakthroughs are more certain. At Zinnov, we believe that India’s GCCs are becoming central to how the pharma industry reimagines itself with AI. The result: life-saving therapies reaching patients faster, and India stepping up as a critical hub in the global pharma industry. What bold bets must India’s GCCs take to stay ahead and shape the future of global healthcare? Share your thoughts in the comments.   Naveen Gullapalli, Amgen India; Sadhna Joglekar, Novartis; John Dawber, Novo Nordisk, Avik Das, Nitika Goel (She/Her), Adnan Furniturewalla, Janice Vaz

42

1 Comment

Artificial Intelligence is transforming pharmacovigilance, making it an essential tool rather than an experimental one. Regulatory bodies like the FDA are actively supporting AI adoption through initiatives such as the Emerging Drug Safety Technology Program. Effective AI integration requires a holistic approach, aligning people, processes, and technology. Archana Hegde shares how AI is revolutionizing drug safety and what it means for the future of PV. Read the full article and gain valuable insights: https://bit.ly/4pohF4s #pv #pharmacovigilance #ai #FDA #EDST

53

The life sciences industry generates some of the world’s highest volumes of data — information that must be scrupulously accurate and carefully guarded but also shareable with healthcare professionals and teams who need to use it on behalf of patients. With AI, life sciences organizations can cut through the noise and simplify engagement with healthcare organizations, allowing them to spend more time with their patients. That’s why a growing number of the world’s leading pharmaceutical, medical technology, and contract research organizations (CROs) have purchased Salesforce’s Agentforce-enabled Life Sciences Cloud to integrate sales, service, marketing, and clinical data on one, end-to-end deeply unified Platform to help ensure that healthcare professionals (HCPs) and their patients get the right information at the right time, ultimately improving access to therapies. More than 70 industry leaders — including Fresenius Kabi, Pfizer, Takeda — have entrusted Life Sciences Cloud as their intelligent solution to connect clinical, commercial, and patient care operations. Now, clinical trial sites and sponsors can use AI to recruit the optimal, diverse group of candidates or trial location or identify the best location for a study, field sales reps can do things like make the most of their interactions with HCPs by using assistants to prep for visits and follow-up, and patient services teams can use agents to automate coverage analysis, proactive alerts, and bulk verifications and leverage insights to help improve medication adherence. Life Sciences Cloud is purpose-built for clinical trial recruitment, patient services, and HCP engagement for Pharma and MedTech organizations. https://sforce.co/4oYlHjS

74

4 Comments

Here’s our CDISC Technology Vendor Roundtable at US Interchange 2025! This is a collaborative initiative designed to bring together technology vendors to accelerate the development and adoption of CDISC standards, especially in support of the 360i vision for a connected clinical research lifecycle. This roundtable plays a role in shaping the future of clinical trials by ensuring that CDISC standards are practical and implementable in modern digital workflows. It supports the broader 360i initiative by helping vendors and developers build tools that integrate seamlessly with CDISC’s structured metadata and digital protocol models. #CDISC2025US #ClearDataClearImpact #CDISC360i

84

4 Comments

#CommsCast | #Exclusive | Srikanth Ayyappan, Senior Director, Marketing and Strategy, Parexel India, joins Christina Dsouza-Lasrado, Group Head – Integrated Healthcare Practice (IHCP), Adfactors PR, on #COMMSCAST – The Reputation Podcast powered by Adfactors PR. In this episode, Srikanth shares his perspective on generative AI as a “super-assistant” that boosts productivity and efficiency, while underscoring that human creativity, emotional intelligence, and judgment remain irreplaceable. 🔗 Watch the full episode here: https://lnkd.in/dkSq6V9i #mediabrief #SrikanthAyyappan #SeniorDirectorMarketingandStrategy #ParexelIndia #ChristinaDsouzaLasrado #GroupHead #IntegratedHealthcarePractice #IHCP #AdfactorsPR #COMMSCASTTheReputationPodcast #TheReputationPodcast #videopodcasts #podcasts #AIinhealthcaremarketing #Authenticity #empathy #GenerativeAI #HealthcareMarketing #reputationmanagement #technology #marketing #media

16